vs
CARVANA CO.（CVNA）与吉利德科学（GILD）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是CARVANA CO.的1.4倍（$7.9B vs $5.6B），吉利德科学净利率更高（27.5% vs 15.3%，领先12.3%），CARVANA CO.同比增速更快（58.0% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $379.0M），过去两年CARVANA CO.的营收复合增速更高（35.3% vs 8.9%）
Carvana Co.是总部位于美国亚利桑那州坦佩市的线上二手车零售企业，主打线上一站式购车服务，2021年成功入选《财富》500强榜单，是该榜单有史以来最年轻的上榜企业之一。
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
CVNA vs GILD — 直观对比
营收规模更大
GILD
是对方的1.4倍
$5.6B
营收增速更快
CVNA
高出53.3%
4.7%
净利率更高
GILD
高出12.3%
15.3%
自由现金流更多
GILD
多$2.7B
$379.0M
两年增速更快
CVNA
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.6B | $7.9B |
| 净利润 | $857.0M | $2.2B |
| 毛利率 | 18.8% | 79.5% |
| 营业利润率 | 7.6% | 25.0% |
| 净利率 | 15.3% | 27.5% |
| 营收同比 | 58.0% | 4.7% |
| 净利润同比 | 984.8% | 22.4% |
| 每股收益（稀释后） | — | $1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVNAGILD
| Q4 25 | $5.6B | $7.9B | ||
| Q3 25 | $5.6B | $7.8B | ||
| Q2 25 | $4.8B | $7.1B | ||
| Q1 25 | $4.2B | $6.7B | ||
| Q4 24 | $3.5B | $7.6B | ||
| Q3 24 | $3.7B | $7.5B | ||
| Q2 24 | $3.4B | $7.0B | ||
| Q1 24 | $3.1B | $6.7B |
净利润CVNAGILD
| Q4 25 | $857.0M | $2.2B | ||
| Q3 25 | $151.0M | $3.1B | ||
| Q2 25 | $183.0M | $2.0B | ||
| Q1 25 | $216.0M | $1.3B | ||
| Q4 24 | $79.0M | $1.8B | ||
| Q3 24 | $85.0M | $1.3B | ||
| Q2 24 | $18.0M | $1.6B | ||
| Q1 24 | $28.0M | $-4.2B |
毛利率CVNAGILD
| Q4 25 | 18.8% | 79.5% | ||
| Q3 25 | 20.3% | 79.8% | ||
| Q2 25 | 22.0% | 78.8% | ||
| Q1 25 | 22.0% | 76.9% | ||
| Q4 24 | 21.5% | 79.1% | ||
| Q3 24 | 22.1% | 79.1% | ||
| Q2 24 | 21.0% | 77.8% | ||
| Q1 24 | 19.3% | 76.8% |
营业利润率CVNAGILD
| Q4 25 | 7.6% | 25.0% | ||
| Q3 25 | 9.8% | 42.8% | ||
| Q2 25 | 10.6% | 34.9% | ||
| Q1 25 | 9.3% | 33.6% | ||
| Q4 24 | 7.3% | 32.4% | ||
| Q3 24 | 9.2% | 11.8% | ||
| Q2 24 | 7.6% | 38.0% | ||
| Q1 24 | 4.4% | -64.6% |
净利率CVNAGILD
| Q4 25 | 15.3% | 27.5% | ||
| Q3 25 | 2.7% | 39.3% | ||
| Q2 25 | 3.8% | 27.7% | ||
| Q1 25 | 5.1% | 19.7% | ||
| Q4 24 | 2.2% | 23.6% | ||
| Q3 24 | 2.3% | 16.6% | ||
| Q2 24 | 0.5% | 23.2% | ||
| Q1 24 | 0.9% | -62.4% |
每股收益（稀释后）CVNAGILD
| Q4 25 | — | $1.75 | ||
| Q3 25 | — | $2.43 | ||
| Q2 25 | — | $1.56 | ||
| Q1 25 | — | $1.04 | ||
| Q4 24 | — | $1.43 | ||
| Q3 24 | — | $1.00 | ||
| Q2 24 | — | $1.29 | ||
| Q1 24 | $0.24 | $-3.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $68.0M |
| 总债务越低越好 | $4.9B | $24.9B |
| 股东权益账面价值 | $3.4B | $22.7B |
| 总资产 | $13.2B | $59.0B |
| 负债/权益比越低杠杆越低 | 1.43× | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资CVNAGILD
| Q4 25 | $2.3B | $68.0M | ||
| Q3 25 | $2.1B | $19.0M | ||
| Q2 25 | $1.9B | $69.0M | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $871.0M | — | ||
| Q2 24 | $542.0M | — | ||
| Q1 24 | $252.0M | — |
总债务CVNAGILD
| Q4 25 | $4.9B | $24.9B | ||
| Q3 25 | — | $24.9B | ||
| Q2 25 | — | $24.9B | ||
| Q1 25 | — | $25.0B | ||
| Q4 24 | $5.3B | $26.7B | ||
| Q3 24 | — | $23.2B | ||
| Q2 24 | — | $23.3B | ||
| Q1 24 | — | $25.2B |
股东权益CVNAGILD
| Q4 25 | $3.4B | $22.7B | ||
| Q3 25 | $2.3B | $21.5B | ||
| Q2 25 | $1.7B | $19.7B | ||
| Q1 25 | $1.5B | $19.2B | ||
| Q4 24 | $1.3B | $19.3B | ||
| Q3 24 | $611.0M | $18.5B | ||
| Q2 24 | $526.0M | $18.3B | ||
| Q1 24 | $289.0M | $17.5B |
总资产CVNAGILD
| Q4 25 | $13.2B | $59.0B | ||
| Q3 25 | $9.9B | $58.5B | ||
| Q2 25 | $9.4B | $55.7B | ||
| Q1 25 | $8.9B | $56.4B | ||
| Q4 24 | $8.5B | $59.0B | ||
| Q3 24 | $7.4B | $54.5B | ||
| Q2 24 | $7.2B | $53.6B | ||
| Q1 24 | $7.0B | $56.3B |
负债/权益比CVNAGILD
| Q4 25 | 1.43× | 1.10× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.30× | ||
| Q4 24 | 4.20× | 1.38× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $430.0M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $379.0M | $3.1B |
| 自由现金流率自由现金流/营收 | 6.8% | 39.4% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.50× | 1.52× |
| 过去12个月自由现金流最近4个季度 | $889.0M | $9.5B |
8季度趋势，按日历期对齐
经营现金流CVNAGILD
| Q4 25 | $430.0M | $3.3B | ||
| Q3 25 | $345.0M | $4.1B | ||
| Q2 25 | $29.0M | $827.0M | ||
| Q1 25 | $232.0M | $1.8B | ||
| Q4 24 | $60.0M | $3.0B | ||
| Q3 24 | $403.0M | $4.3B | ||
| Q2 24 | $354.0M | $1.3B | ||
| Q1 24 | $101.0M | $2.2B |
自由现金流CVNAGILD
| Q4 25 | $379.0M | $3.1B | ||
| Q3 25 | $307.0M | $4.0B | ||
| Q2 25 | $-2.0M | $720.0M | ||
| Q1 25 | $205.0M | $1.7B | ||
| Q4 24 | $36.0M | $2.8B | ||
| Q3 24 | $376.0M | $4.2B | ||
| Q2 24 | $332.0M | $1.2B | ||
| Q1 24 | $83.0M | $2.1B |
自由现金流率CVNAGILD
| Q4 25 | 6.8% | 39.4% | ||
| Q3 25 | 5.4% | 51.0% | ||
| Q2 25 | -0.0% | 10.2% | ||
| Q1 25 | 4.8% | 24.8% | ||
| Q4 24 | 1.0% | 37.4% | ||
| Q3 24 | 10.3% | 55.2% | ||
| Q2 24 | 9.7% | 17.2% | ||
| Q1 24 | 2.7% | 31.6% |
资本支出强度CVNAGILD
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 0.7% | 1.9% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.6% | 1.6% | ||
| Q4 24 | 0.7% | 1.9% | ||
| Q3 24 | 0.7% | 1.9% | ||
| Q2 24 | 0.6% | 1.9% | ||
| Q1 24 | 0.6% | 1.6% |
现金转化率CVNAGILD
| Q4 25 | 0.50× | 1.52× | ||
| Q3 25 | 2.28× | 1.35× | ||
| Q2 25 | 0.16× | 0.42× | ||
| Q1 25 | 1.07× | 1.34× | ||
| Q4 24 | 0.76× | 1.67× | ||
| Q3 24 | 4.74× | 3.44× | ||
| Q2 24 | 19.67× | 0.82× | ||
| Q1 24 | 3.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVNA
| Used Vehicle Sales | $4.2B | 74% |
| Wholesale Sales And Revenues | $988.0M | 18% |
| Other | $459.0M | 8% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
